EVEdgar Felipe Carranza Vargas

Edgar Felipe Carranza Vargas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edgar Felipe Carranza Vargas has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Data-Driven Anesthesiology: The Expanding Role of Artificial Intelligence in Predicting Perioperative Risks

    by Ricardo Xavier Cárdenas Zambrano, Paulina Gutiérrez Medina, Edgar Felipe Carranza Vargas, Jesus Elias Benedetti López, Junior Antonio Barreto Acevedo, Daniel Alberto Madrid Gonzalez, Ingrid Monserrat Jaimes Hernandez, Jorge Angel Velasco Espinal

    Artificial intelligence (AI) has rapidly become one of the most significant technological innovations influencing modern anesthesiology. This review synthesizes recent evidence regarding the use of AI-based systems for perioperative risk prediction, intraoperative monitoring, clinical decision support, and postoperative surveillance. Across multiple studies, machine-learning models demonstrated superior predictive accuracy compared with conventional clinical tools, particularly in identifying patients at risk for postoperative complications and anticipating episodes of intraoperative hemodynamic instability. Predictive systems based on arterial waveform analysis and deep-learning architectures consistently detected hypotension minutes before its clinical onset, allowing for more proactive management. Additionally, AI-enhanced interventions improved adherence to best practices, reduced variability in clinical decision-making, and strengthened early detection of physiologic deterioration. However, despite these promising advances, the literature also highlights important challenges. External validation remains limited, with many models showing reduced performance when applied to new populations or different healthcare systems. Issues of transparency, explainability, and ethical implementation continue to hinder adoption, especially for complex deep-learning models. Infrastructure constraints in low- and middle-income countries further complicate implementation, emphasizing the need for context-adapted strategies. For healthcare systems in Mexico, Colombia, and Ecuador, the integration of AI offers opportunities to enhance perioperative safety but requires careful attention to local resource variability and workforce readiness. Overall, AI represents a powerful adjunct to anesthesiology practice when used with appropriate oversight, ethical safeguards, and clinical judgment. Its continued development and responsible implementation hold substantial potential to improve patient safety, optimize perioperative care, and strengthen health system performance internationally.

  • Open Access

    Optimized Antifibrotic Therapy on Cardiac and Pulmonary Function in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review of Diagnostic and Therapeutic Approaches

    by Syndy Katherine Guarin-Rivera, Gabriela Patricia Guijarro Reinoso, Norma Susana Chávez Villagómez, Jonattan Palacios Torres, Dario Javier Caguate Miranda, Nicole Carolina Sotomayor Páez, Alexander David Silva, Edgar Felipe Carranza Vargas, Pedro Ergir Tomay Madrigal

    Idiopathic Pulmonary Fibrosis (IPF) is progressive interstitial lung disease which is characterized by fibrosis of lung tissue which impair respiratory function and is seen with high mortality. Our systematic review evaluates impact of optimized antifibrotic therapies while including pirfenidone, nintedanib, and BI 1015550 on pulmonary and cardiac function in IPF patients. Comprehensive analysis with previous randomized controlled trials, cohort studies and observational data was performed to assess efficacy in slowing forced vital capacity (FVC) decline, improving prognosis and managing adverse events. Our findings indicate that antifibrotic therapies can mitigate FVC decline and reduce mortality with pirfenidone and nintedanib have shown tolerable safety profiles. BI 1015550 have also shown promising results in preventing FVC reduction and pulmonary rehabilitation alongside antifibrotic treatment improved endurance but not functional capacity. Reported limitations of the included studies include variability in study designs and potential biases from non-randomized trials. Despite these challenges antifibrotic therapies represent a critical advancement in IPF management preserving lung function and potentially enhancing quality of life.